Cargando…
Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382358/ https://www.ncbi.nlm.nih.gov/pubmed/22745915 http://dx.doi.org/10.5402/2012/163752 |
_version_ | 1782236487794819072 |
---|---|
author | Specenier, Pol Vermorken, Jan B. |
author_facet | Specenier, Pol Vermorken, Jan B. |
author_sort | Specenier, Pol |
collection | PubMed |
description | The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA). |
format | Online Article Text |
id | pubmed-3382358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-33823582012-06-28 Biologic Therapy in Head and Neck Cancer: A Road with Hurdles Specenier, Pol Vermorken, Jan B. ISRN Oncol Review Article The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA). International Scholarly Research Network 2012-06-13 /pmc/articles/PMC3382358/ /pubmed/22745915 http://dx.doi.org/10.5402/2012/163752 Text en Copyright © 2012 P. Specenier and J. B. Vermorken. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Specenier, Pol Vermorken, Jan B. Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title | Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title_full | Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title_fullStr | Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title_full_unstemmed | Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title_short | Biologic Therapy in Head and Neck Cancer: A Road with Hurdles |
title_sort | biologic therapy in head and neck cancer: a road with hurdles |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382358/ https://www.ncbi.nlm.nih.gov/pubmed/22745915 http://dx.doi.org/10.5402/2012/163752 |
work_keys_str_mv | AT specenierpol biologictherapyinheadandneckcanceraroadwithhurdles AT vermorkenjanb biologictherapyinheadandneckcanceraroadwithhurdles |